← Leaderboards
Erin Wei
Dana-Farber Cancer Inst
$1,014,029
Attributed
$2,028,057
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $700.7K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$2,028,057 · 1
By mechanism
R01$2,028,057 · 1
Top collaborators
- Mohammad Rashidian3 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Shannon J Turley$5,420,711
- Matthew S Davids$2,319,476
- Mohammad Rashidian$1,587,857
- Kai W Wucherpfennig$37,935,181
- Laurie H Glimcher$56,303,115
Others in their field
Other Rising Stars on “Adhesions”
- John Paderi John Paderi John Paderi · Ihp Therapeutics, Inc.$5,881,537
- Hyunwoo Yuk · Sanaheal, Inc.$4,709,498
- Bozena Korczak · Vascular Vision Pharmaceuticals Company$3,058,782
- Osama Al Dalahmah · Columbia University Health Sciences$2,957,210
- Ming He · University Of California, San Diego$2,917,239
- Todd McFarland · Cerulean Scientific Inc.$2,720,353
Research focus
AdhesionsAffectAffinityAdultAnimal ModelAnimalsAntagonistAntibodiesAgammaglobulinaemia Tyrosine KinaseAntigensAntigen TargetingAutoantibodiesAutoantigensAutoimmune DiseasesAutologousAutoreactive B CellAutoreactivityBasement MembraneB-Cell Antigen ReceptorBindingBiological ProductsBioluminescenceB-LymphocytesBulla
Grant awards (3)
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases$663,019
R01 · FY2025 · AI
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases$664,312
R01 · FY2024 · AI
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases$700,726
R01 · FY2023 · AI